StreetAlpha.app
Home › Stocks › PMCB

PharmaCyte Biotech, Inc. (PMCB)

$5.39
▼ −5.11%
LAST CLOSE · NOV 17

PharmaCyte Biotech develops cancer cell therapies using its Cell-in-a-Box encapsulation technology, based in Las Vegas. It last closed at $5.39 on Nov 17, down 5.11% on the day. PMCB reports earnings on Wed, Dec 16, 2026.

AI Auto Pilots
Is PMCB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$16.1M
EPS (diluted)
−$2.08
−3566.7% vs a year ago
Valuation
Market cap
$57.9M
10.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$17.7M
At Jul 31
Shareholder equity
$27.5M
Shares outstanding
10.7M
At Sep 11
Fiscal year endsApril
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025FY2026: $0$0FY2026

From PMCB's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 14). Last 12 months adds up the four latest quarters.

Next report
Dec 16
2026 · Time not announced
Consensus EPS forecast
-$0.06
 
Year-ago EPS
-$1.24
Same quarter last year
Options-implied move
—
Posted about a week before
Analyst consensus
—
No ratings in 90 days
Loading…

Technical Analysis

PMCB · as of the Nov 17 close · updated after every close
Uptrend, overbought

The stock is 78% above its 20 day and 87% above its 50 day average. It is 87% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 80), overbought. The nearest support is the Pivot S1 at $5.37, and the nearest resistance the Pivot at $5.41.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityHigh, 11.7%/day
Key levels
$8.1752 week high+51.6%
$5.43Pivot R1+0.7%
$5.41Pivot+0.4%
$5.39Last close
$5.37Pivot S1−0.4%
$1.2020 day average−77.7%
$0.7250 day average−86.6%
$0.71Swing low (Jun 22)−86.8%
$0.70200 day average−87.0%
$0.66100 day average−87.8%
$0.2552 week low−95.4%
Indicators
RSI (14)79.81Overbought above 70Overbought
MACD1.03Above its signal lineBullish
Stochastic72.1Middle of its rangeNeutral
ADX (14)31.3Trending up
Williams %R-35.1Oversold below −80, overbought above −20Neutral
CCI (20)188.0Oversold below −100, overbought above 100Overbought
Rate of change+1484.8%Change over 10 sessionsBullish
ATR (14)$0.63Typical daily range, 11.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PMCB

What happened before

See how PMCB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PMCB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PMCB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PMCB in the last 90 days.

Loading…

See today’s whale options flow across the market →

PMCB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼6 buying vs 18 selling
  • ▼Held by funds -0.8 pts
  • ▼Funds holding -6
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2733−18.2%
In funds' top 1000–
Held by funds6.3%7.1%−0.8 pts
New / increased4 / 24 / 6−40.0%
Reduced / sold out9 / 99 / 6+20.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PMCB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMCB is in one of them and how their past PMCB trades turned out.

PMCB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PMCB in an article yet. Here's the latest on the wider market.

About PharmaCyte Biotech

PharmaCyte Biotech is a biotechnology company based in Las Vegas, Nevada, that develops cell therapies for cancer. Its Cell-in-a-Box technology places genetically engineered live human cells inside small capsules made mostly of cellulose, which are positioned near a tumor. Its main product candidate, CypCaps, is being developed for patients with locally advanced pancreatic cancer. Spending on these development programs has been reduced while the company reviews them.

Headquarters
Las Vegas, NV